In sub-Saharan Africa, 55% of the estimated 28.5 million HIV-1 infected individuals are women, and approximately 90% of these are between the ages of 15 and 49 years . Thus, counseling about family planning methods is an essential part of health care for most HIV-1 infected women. In a recent reproductive health survey of women in sub-Saharan Africa and Southeast Asia, 30–40% of those using family planning had chosen oral contraceptives (OC). In some countries, depot medroxyprogesterone acetate (Depo) is more commonly used than OC. For example, in a survey in Kenya, 22% of women using family planning used OC and 30% used Depo .
More than 20 studies have investigated whether use of OC or Depo is associated with increased susceptibility to HIV-1. A meta-analysis of published studies addressing the relationship between OC and HIV-1 susceptibility reported an increased risk, with an odds ratio (OR) of 1.19 [95% confidence interval (CI), 0.99–1.42] for 28 studies . This OR increased when the analysis was limited to the eight most rigorous studies (OR, 1.60; 95% CI, 1.05–2.44).
Other authors have focused on the effect of hormonal contraception on the infectivity of HIV-1 infected women. In a cross-sectional study of 318 women, the detection of HIV-1 DNA in cervical fluids was significantly associated with use of Depo, low-dose OC, and high-dose OC . In another cross-sectional study, hormonal contraception was not found to increase genital tract shedding of HIV-1 RNA . To provide more definitive data on the effect of hormonal contraception on the infectivity of HIV-1 seropositive women, we conducted a prospective study, with cervical secretions collected before and after initiation of high- and low-dose combination OC, progesterone-only pills, and Depo injections. In this study, a qualitative assay was used to detect the presence of HIV-1 proviral DNA, a marker for infected cells. A quantitative assay was used to measure the concentration of HIV-1 RNA (both cell-associated and cell-free virus) in cervical secretions.
Study population and procedures
From August 1996 to September 1998, women attending outpatient clinics at Coast Provincial General Hospital in Mombasa, Kenya were recruited if they planned to initiate hormonal contraception. First, informed consent for HIV serologic testing was obtained. Women testing positive for HIV-1 antibodies using a rapid detection assay underwent a second informed consent process for the prospective study.
After completing an enrollment questionnaire regarding demographic, sexual, and obstetric history, a physical examination was performed. Cervical secretions for HIV-1 DNA and RNA assays were collected by placing successive Dacron swabs gently into the cervical os and turning three times. The presence of 5% or more of the cervical surface displaying endocervical mucosa on speculum examination was defined as cervical ectopy.
Cervical and vaginal secretions were also collected to assess the presence of genital infections. Examinations and sample collections were performed by one of two investigators (C.C.W. or R.S.M.).
Women were eligible for the study if they did not have genital ulcers on examination or microbiologic evidence of any genital infections with the exception of bacterial vaginosis. Women with genital infections were given appropriate treatment and asked to return in 2 weeks. If at the second visit their infections had resolved, they were eligible for the study.
Women were given oral contraception pills or Depo injections, depending on their choice. Depo or progesterone-only pills were dispensed to women who were breastfeeding. High-dose estrogen combination pills were dispensed for the first three months of the study and low-dose estrogen combination pills thereafter once they became available.
Follow-up visits were scheduled at 1 and 2 months after initiation of contraception. Follow-up visits were included in the analysis if they occurred 14 to 120 days after the initial visit. If more than one follow-up visit occurred, the latter visit was used (154 cases). Comparison of paired visits was performed separately for cervical RNA concentration, prevalence of cervical DNA detection, prevalence of cervical RNA detection, and plasma RNA concentration. Because of missing samples, 10 women, two women, and 17 women were excluded from the analyses of cervical RNA, cervical DNA, and plasma RNA assay results, respectively.
Diagnoses and evaluation of HIV-1, cervical infections, and vaginal conditions were performed as described previously [6,7]. CD4 lymphocytes were quantified in EDTA-anticoagulated whole blood by a manual method (Cytosphere; Coulter, Hialeah, Florida, USA).
Plasma and cervical swabs for HIV-1 DNA and RNA detection were stored and shipped as described previously, with care to maintain the cold chain throughout .
Samples were assayed in batches of swab pairs. A qualitative PCR was used to measure the presence of HIV-1 DNA (a marker of HIV-1 infected cells), as described previously . Quantitative levels of HIV-1 RNA (both cell-associated and cell-free) were measured with the Gen-Probe HIV-1 viral load assay (Gen-Probe Inc., San Diego, California, USA) with a sensitivity of 92% (95% CI, 85 - 98%) and a specificity of 98% (95% CI, 93–100%) . For the study presented here, the lower limit of quantification used reflects the adjustment for the appropriate dilution factors used; 15 copies/cervical swab and 7 copies/ml plasma. In our swab analysis, any value less than 15 was assigned the value of 14 copies/cervical swab and was considered undetectable.
Data analysis was performed using Stata 7.0 (Stata, College Station, Texas, USA) and SPSS 10.1.3 (SPSS Inc., Chicago, Illinois, USA) software. Paired results before and after initiation of hormonal contraception were compared using McNemar's test for dichotomous variables and paired t-tests for continuous variables. For the analysis of cervical RNA shedding and plasma RNA levels, we used the ratio of the levels of RNA before and after initiation of contraception, on a log scale, as this measure was normally distributed for cervical shedding and approximately normal for plasma levels. Power calculations were performed using Excel 2000 (Microsoft Corporation, Redmond, Washington, USA).
The demographic characteristics of the 213 women included in the study analysis are presented in Table 1. Over two-thirds of women (68%) were breastfeeding at the time of the initial visit, necessitating the choice of a progesterone-only hormonal contraceptive. Forty-eight percent of women chose to use Depo, 25% low-dose combination OC, 24% progesterone-only OC, and 3% high-dose combination OC before low-dose OC were available. Twenty percent of women had severe immunosuppression, with CD4 cell counts < 106 cells/l.
Median follow-up was 64 days (range, 25—120 days). At baseline, 42% of women had detectable cervical HIV-1 DNA (Table 2). When data from women using all forms of hormonal contraception were combined, the prevalence of cervical HIV-1 DNA detection increased significantly at the follow-up visit (from 42% to 52%; P = 0.03). When women were divided into groups based on the individual forms of contraception used, an increase in the prevalence of HIV-1 DNA detection was noted in all groups, but this was not statistically significant. However, the statistical power to detect a 1.5-fold increase in shedding was only 34% for Depo, and 23% for low-dose and progesterone-only OC.
For all women combined, 82% and 86% had quantifiable cervical HIV-1 RNA concentrations before and after initiation of hormonal contraception, respectively (P = 0.18). Overall, no change in mean cervical or plasma HIV-1 RNA concentration was detected (2.81 to 2.84 log10 copies/swab, P = 0.77 and 4.84 to 4.88 log10 copies/ml, P = 0.47, respectively). Although no significant changes in prevalence or concentration of cervical HIV-1 RNA was noted for individual hormonal contraceptive types during follow-up, there was a slight increase in both the prevalence and the concentration of HIV-1 RNA shedding for all groups except the high-dose OC. Finally, no significant changes in plasma HIV-1 RNA concentration were noted for individual hormonal contraceptive methods.
In this prospective study, women initiating hormonal contraception demonstrated a modest but significant increase in the prevalence of HIV-1 infected cells (from 42% to 52%; P = 0.03) and a slight increase in the prevalence of HIV-1 RNA detection in cervical secretions, although this was not statistically significant (from 81% to 86%; P = 0.18). No changes were detected in the concentration of cervical HIV-1 RNA, but our power to detect small changes was limited. In addition, plasma HIV-1 RNA concentration did not change.
The findings from this prospective study support previous findings of a cross-sectional study showing that cervical shedding of HIV-1 infected cells was significantly higher among 55 women using Depo (OR, 2.9; 95% CI, 1.5–5.7), 25 women using low-dose OC (OR, 3.8; 95% CI, 1.4–9.9), and 11 women using high-dose OC (OR, 12.3; 95% CI, 1.5–101) for a minimum of 6 months compared to women not using hormonal contraception . Levels of viral RNA were not examined, but it was assumed that HIV-1 RNA would also increase because infected cells are thought to be the primary source of cell-free virus .
In our study, the increase in cervical HIV-1 proviral DNA without a commensurate increase in the concentration of cervical HIV-1 RNA was surprising, although not inconsistent with the findings of two other cross-sectional studies [4,10]. Our data suggest that the increase in infected cells in cervical secretions may reflect an influx of infected cells from systemic compartments rather than changes in local virus replication. In such a model, hormonal changes would not influence the levels of virus replication in the genital mucosa, but would alter the number and types of infected cells in the mucosa. Over time, the concentration of replicating virus may increase slowly in response to increases in the number of infected cells. However, our follow-up period may have been too short to detect these changes.
These findings demonstrate that short-term use of hormonal contraception by HIV-1 infected women is associated with a modest increase in shedding of HIV-1 infected cells, but not of the concentration of HIV-1 RNA, although we had low power to detect the latter. The relative impact of HIV-1 proviral DNA versus HIV-1 RNA on infectivity is uncertain, but the presence of HIV-1 provirus and HIV-1 RNA in maternal cervical secretions [11,12] and breastmilk  have been found to increase vertical transmission risk.
Hormonal contraception is an effective, affordable contraceptive method . However, these results raise the possibility that use of hormonal contraception may increase the infectivity of HIV-1 infected women to uninfected partners, thus providing another reason for barrier contraception for partner protection. This study may provide guidance for future studies of hormonal contraception and shedding in HIV-1 infected women, incorporating longer follow-up periods, as well as the enumeration of mucosal lymphocyte populations. In addition, epidemiologic studies to determine if HIV-1 transmission rates by women using hormonal contraception differ from women not using hormonal contraception would provide valuable information about the effect of hormonal contraception on infectivity of HIV-1 infected women.
We thank our research nurse, M. Wamugunda, as well as the STD and antenatal clinics at Coast General Hospital for their assistance with this project. We thank the study women, without whom this study would not have been possible. We acknowledge Gen-Probe for providing reagents for RNA assays, and for helpful discussions. Our thanks go to A. Abdalla, G. Maina, K. Mushahame, and B. Ouma in the research laboratory. Finally, we thank J. Gow for her skillful administrative support.
Sponsorship: Supported in part by a grant from the National Institutes of Health (R01-AI39996). C. Wang and R. McClelland were scholars in the International AIDS Research and Training Program supported by the Fogarty International Center (D43-TW00007, T22-TW00001).
1. UNAIDS. Report on the Global HIV/AIDS Epidemic 2002.
Geneva: UNAIDS Information Center; 2002.
2. Blackburn R, Cunkelman J, Zlidar V. Oral Contraceptives – An Update.
Population Reports, Johns Hopkins University School of Public Health, Population Information Program Spring 2000, Series A.
3. Wang CC, Reilly M, Kreiss JK. Risk of HIV infection in oral contraceptive pill users: a meta-analysis. J Acquir Immune Defic Syndr
4. Mostad SB, Overbaugh J, DeVange DM, Welch MJ, Chohan B, Mandaliya K, et al
. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet
5. Kovacs A, Wasserman SS, Burns D, Wright DJ, Cohn J, Landay A, et al
. Determinants of HIV-1 shedding in the genital tract of women. Lancet
6. McClelland RS, Wang CC, Mandaliya K, Overbaugh J, Reiner MT, Panteleeff DD, et al
. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS
7. Wang CC, McClelland RS, Reilly M, Overbaugh J, Emery SR, Mandaliya K, et al
. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis
8. Moss GB, Overbaugh J, Welch M, Reilly M, Bwayo J, Plummer FA, et al. Human immunodeficiency virus DNA in urethral secretions in men: association with gonococcal urethritis and CD4 cell depletion. J Infect Dis
9. Panteleeff DD, Emery S, Richardson BA, Rousseau C, Benki S, Bodrug S, et al
. Validation of performance of the Gen-Probe Human Immunodeficiency Virus Type I Viral Load Assay with genital swabs and breast milk samples. J Clin Microbiol
10. Kovacs A, Chan LS, Chen ZC, Meyer WA, Muderspach L, Young M, et al
. HIV-1 RNA in plasma and genital tract secretions in women infected with HIV-1. J Acquir Immune Defic Syndr
11. John GC, Nduati RW, Mbori-Ngacha DA, Richardson BA, Panteleeff D, Mwatha A, et al
. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA Load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis
12. Panther LA, Tucker L, Xu C, Tuomala RE, Mullins JI, Anderson DJ. Genital tract human immunodeficiency virus type 1 (HIV-1) shedding and inflammation and HIV-1 env diversity in perinatal HIV-1 transmission. J Infect Dis
13. Semba RD, Miotti PG, Chiphangwi JD, Saah AJ, Canner JK, Dallabetta GA, et al
. Maternal vitamin A deficiency and mother-to-child transmission of HIV-1. Lancet
14. Technical Guidance/Competence Working Group. Family Planning Methods, New Guidance.
Population Reports, Johns Hopkins University School of Public Health, Population Information Program October 1996, Series J.